Effect of different ERK2 protein localizations on prognosis of patients with invasive breast carcinoma

APMIS

Volumn 113, Issue 10, 2005, Pages 693-701

  Nakopoulou, L ^a,b   Mylona, E ^a   Rafailidis, P ^a   Alexandrou, P ^a   Giannopoulou, I ^a   Keramopoulos, A ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; ERK2 kinase; MMP 11: immunohistochemistry

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; RAF PROTEIN; STROMELYSIN 3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CYTOPLASM; ENZYME PHOSPHORYLATION; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 28844443277     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2005.apm_236.x     Document Type: Article

References (37)

1. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999;79:143-80.
2. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science 2002;298:1911-2.
3. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
4. Reszka AA, Bulinski JC, Krebs EG, Fischer EH. Mitogen-activated protein kinase extracellular signal-regulated kinase-2 regulates cytoskeletal organization and chemotaxis via catalytic and microtubule-specific interactions. Mol Biol Cell 1997;8:1219-32.
5. Mineo C, Anderson RW, White MA. Physical association with Ras enhances activation of membrane-bound Raf (Raf-CAAX). J Biol Chem 1997;272:10345-8.
6. Chen RH, Sarnecki C, Blerus J. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol 1992;12:915-27.
7. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signaling. Biochem Pharmacol 2002;64:775-63.
8. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J. Mitogen-activated protein kinases P42mapk and P44mapk are required for fibroblast cell proliferation. Proc Natl Acad Sci USA 1993;90:8319-23.
9. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 1992;282:351-5.
10. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
11. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
12. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumors. Br J Cancer 2004;90:1047-52.
13. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
14. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
15. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704.
16. Nakopoulou L, Panayotopoulou G, Giannopoulou I, Alexandrou P, Katsarou S, Athanassiadou P, Keramopoulos A. Stromelysin-3 protein expression in invasive breast carcinoma: relation to proliferation, cell survival and patients' outcome. Mod Pathol 2002;15:1154-61.
17. Luttrell LM. Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. Can J Physiol Pharmacol 2002;80:375-82.
18. Masson R, Lefebvre R, Noel A, Fahime ME, Chenard MP, Wendung C, Kebers F, LeMeur M, Dierich A, Foidart JM, Basset P. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-41.
19. World Health Organization. Histological typing of breast tumours. In: Hartman WH, Uzello L, Sobin LH, Stalsberg H, editors. International Histological Classification of Tumours. 2nd ed. Geneva, 1981:15-25.
20. Robins P, Finder S, de Klerk N. Histological grading of breast carcinomas: a study of inter-observer agreement. Hum Pathol 1995;28:873-9.
21. Kinne DW. Staging and follow-up of breast cancer patients. Cancer 1991;67:1196-8.
22. McClelland RA, Wilson D, Leake R, Finlay P, Nicholson RI. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991;27:711-6.
23. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000;89:384-8.
24. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-53.
25. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V, Loning T. Expression and prognostic relevance of activated extracellular- regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005;92:2206-15.
26. Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extracellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma. Am J Pathol 2003;163: 957-67.
27. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997; 99:1478-83.
28. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA. Expression and prognostic significance of kit, protein kinase B and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 2003;9:2241-7.
29. Kim-Schulae S, Lowe WL, Schnaper HW. Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor. Circulation 1998;98:413-21.
30. Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee KO, Lobie PE. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res 1999;250:35-50.
31. Bonapace IM, Addeo R, Altucci L, Cicatiello L, Bifulco M, Laezza C, Salzano S, Sica V, Bresciani F, Weisz A. 17B-estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation. Oncogene 1996;12:753-63.
32. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 2000;62:167-75.
33. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001;95:247-54.
34. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 1998;8:1141-50.
35. Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B, Nguyen XT, Barnier JV, Camonis J, Ginsberg MH, Chneiweiss H. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 2001;1:239-50.
36. Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ, Luttrell LM. Beta-arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 2002;277:9429-36. Epub 2002 Jan 2.
37. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. β-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000;148:1267-81.